6-羟甲基吡啶-2-羧酸甲酯 | 39977-44-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-羟甲基吡啶-2-羧酸甲酯
• 中文别名: 6-羟甲基-吡啶-2-甲酸甲酯；6-羟甲基-2-吡啶甲酸甲酯
• 英文名称: methyl 6-(hydroxymethyl)pyridine-2-carboxylate
• 英文别名: methyl 6-(hydroxymethyl)picolinate；6-(hydroxymethyl)pyridine-2-carboxylic acid methyl ester；2-hydroxymethylpyridine-6-carboxylic acid methyl ester；methyl 2-(hydroxymethyl)pyridine-2-carboxylate
• CAS: 39977-44-1
• 化学式: C₈H₉NO₃
• mdl: MFCD03840850
• 分子量: 167.164
• InChiKey: DVIUNMLAPDJWHL-UHFFFAOYSA-N

物化性质

• 熔点：
  178 °C
• 沸点：
  327.3±32.0 °C(Predicted)
• 密度：
  1.244

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 6-(hydroxymethyl)picolinate
Synonyms: Methyl 6-hydroxymethyl-2-pyridinecarboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 6-(hydroxymethyl)picolinate
CAS number: 39977-44-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H9NO3
Molecular weight: 167.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-羟甲基吡啶-2-羧酸甲酯 在 manganese(IV) oxide 、 ammonium hydroxide 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 197.17h， 生成 6,6'-(2-hydroxy-5-methyl-1,3-phenylene)bis(methylene)bis((2-hydroxyethyl)azanediyl) bis(methylene)dipicolinamide
  参考文献：
  名称：

  Ligand modifications modulate the mechanism of binuclear phosphatase biomimetics

  摘要：

  Complexation of dimethyl-6,6'-(2-hydroxy-5-methyl-1,3-phenylene)bis(methylene)bis((2-hydroxyethyl) azanediyl)bis(methylene)dipicolinate (Me(2)H(3)L4) and 2,2'-(2-hydroxy-5-methyl-1,3-phenylene)bis(meth ylene)bis(((6-methylpyridin-2-yl)methy)azanediyl)diethanol (H(3)L5) with Zn(II) afforded the complexes [Zn-2(H(2)L4)(H2O)(2)](ClO4) and [Zn-2(H(2)L5)(CH3CO2)(H2O)](PF6)(2)center dot 2H(2)O, which were characterized by H-1 and C-13 NMR spectroscopy, mass spectrometry, microanalysis, and the former by X-ray crystallography. Functional studies of the zinc complexes with the substrate bis(2,4-dinitrophenyl)phosphate (BDNPP) showed the complexes to be competent catalysts with k(cat) = 3.52 +/- 0.03 x 10(-4) and 1.27 +/- 0.04 x 10(-3) s(-1) (K-m = 6.7 +/- 0.9; 13.8 +/- 1.5 mM), with catalytically relevant pK(a)s of 9.4 and 6.6, respectively. The pK(a) values are discussed with respect to the potential nucleophilic species and the effect of the donor environment. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.06.008
• 作为产物：
  描述：

  吡啶-2.6-二羧酸二甲酯 在 甲醇 、 sodium tetrahydroborate 作用下， 反应 5.0h， 以80%的产率得到6-羟甲基吡啶-2-羧酸甲酯
  参考文献：
  名称：

  H2dedpa衍生物作为新德里Metallo-β-内酰胺酶-1的有效抑制剂的系统研究。

  摘要：

  新德里Metallo-β-内酰胺酶-1（NDM-1）是一种依赖锌（II）的酶，可以催化几乎所有β-内酰胺抗生素（包括碳青霉烯）的水解，导致细菌对抗生素的耐药性，这在全球范围内威胁着公众健康。基于我们的发现，H 2 dedpa是有效的NDM-1抑制剂，系统地制备了一系列H 2 dedpa衍生物。这些化合物对NDM-1表现出显着的活性，IC 50值为0.06-0.94μM。在体外，化合物6k和6n可以恢复美罗培南对肺炎克雷伯菌，大肠杆菌和变形杆菌的活性。拥有NDM或IMP。特别地，当使用这两种化合物时，美罗培南对产生大肠杆菌的NDM-4的活性可提高至5333倍。基于时间杀伤的细胞分析表明，美罗培南与化合物6k或6n联合使用可杀死99.9％的奇异疟原虫。此外，化合物6k和6n具有非溶血性（HC 50  > 1280μg/ mL），并且对哺乳动物（HeLa）细胞毒性低。机理研究表明，化合物6k和6n通过螯合酶的Zn

  DOI：

  10.1016/j.bioorg.2020.103965

文献信息

• [EN] PROCESSES FOR MAKING TRIAZOLO[4,5D] PYRAMIDINE DERIVATIVES AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS DE PREPARATION DE DÉRIVÉS DE TRIAZOLO [4,5 D] PYRIMIDINE ET INTERMÉDIAIRES DE CEUX-CI
  申请人：CORVUS PHARMACEUTICALS INC

  公开号：WO2018183965A1

  公开（公告）日：2018-10-04

  Provided herein are, inter alia, methods for making triazolo[4,5]pyramidine derivatives and intermediates thereof that are useful for treating diseases.

  本文提供了制备三氮杂[4,5]吡啶衍生物及其中间体的方法，这些衍生物对治疗疾病有用。
• Small-molecules that covalently react with a human prolyl hydroxylase – towards activity modulation and substrate capture
  作者：Jacob T. Bush、Robert K. Leśniak、Tzu-Lan Yeh、Roman Belle、Holger Kramer、Anthony Tumber、Rasheduzzaman Chowdhury、Emily Flashman、Jasmin Mecinović、Christopher J. Schofield

  DOI：10.1039/c8cc07706a

  日期：——

  We describe covalently binding modulators of the activity of human prolyl hydroxylase domain 2 (PHD2) and studies towards a strategy for photocapture of PHD2 substrates.

  我们描述了共价结合的人类脯氨酸羟化酶结构域2（PHD2）活性调节剂，并进行了研究，以制定一种用于光捕获PHD2底物的策略。
• Piperidine derivative rennin inhibitors
  申请人：——

  公开号：US20040204455A1

  公开（公告）日：2004-10-14

  Disclosed are piperidine derivatives, their manufacture and use as inhibitors of renin.

  公开了哌啶衍生物，它们的制造方法及其作为肾素抑制剂的用途。
• HIV protease inhibiting compounds
  申请人：DeGoey A. David

  公开号：US20050131017A1

  公开（公告）日：2005-06-16

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种公式的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。
• 2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent
  申请人：Astra Pharmaceuticals Limited

  公开号：US06107297A1

  公开（公告）日：2000-08-22

  The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.

  本发明涉及新的药物活性化合物，这些化合物是P2-嘌呤受体7-跨膜(TM)G-蛋白偶联受体拮抗剂，包含它们的组合物以及它们的制备方法。